I sold on their failed Dacogen AML trial a few years back. Remarkably similar data. Then the EU approved it anyways based on a recalculation of their OS by updating the survival of their right censored patients. They were able to eek out statistical significance. I'll repeat, Dacogen failed just like Rigo did, and the EU approved it anyways. Those that were able to stomach the risk and the wait yielded an 8x return in about 2 years. I'm in here to see history repeat itself.